Navigation Links
SARcode Corporation Announces Phase 2 Study Results of SAR 1118 Topical Ophthalmic Solution for the Treatment of Dry Eye
Date:5/3/2010

SAN FRANCISCO, May 3 /PRNewswire/ -- SARcode Corporation, a privately-held biotechnology company focused on developing a novel class of lymphocyte function-associated antigen-1 (LFA-1) antagonists, today announced results of a 230 patient Phase 2 proof-of-concept study evaluating topical SAR 1118 ophthalmic solution in the treatment of aqueous deficient dry eye (keratoconjunctivitis sicca). The study results were presented at the Dry Eye Summit meeting on April 30th in Fort Lauderdale, Florida, immediately prior to ARVO 2010, the annual meeting of the Association for Research in Vision and Ophthalmology. The study results demonstrated clear improvements in both signs and symptoms of dry eye at 12 weeks. SAR 1118 was well-tolerated, with no serious ocular adverse events reported.  

"We are very pleased with the results of the Phase 2 study," said Charles Semba, MD, chief medical officer of SARcode. "We met our goals of showing improvements in both corneal staining and patient symptoms. We were encouraged too that SAR 1118 achieved these results within 12 weeks, suggesting that it might provide more rapid relief than currently available therapies."

About the Phase 2 Study

The study was a randomized, multicenter, double-masked study comparing SAR 1118 (0.1, 1.0, 5.0%) to placebo. A total of 230 subjects were randomized 1:1:1:1 to receive drops twice daily for 12 weeks. The primary objective measure was inferior corneal staining. The major secondary measures were Ocular Surface Disease Index (OSDI) symptom score and tear production by Schirmer tear test (STT).  

About Dry Eye

Dry eye (keratoconjunctivitis sicca) is a multifactorial disease of the tears and the ocular surface that results in symptoms of discomfort, visual disturbance and tear film instability with the potential to damage the ocular surface. It is accompanied by increased osmolarity of the tear film and inflammation of the ocular surface (Dry Eye Work Shop (DEWS, 2007)).  According to the DEWS report, approximately 5 million patients, 50 years and older, have moderate to severe dry eye. A major contributing factor towards the development of dry eye is T-cell infiltration, proliferation and inflammatory cytokine production in diseased ocular tissues that leads to reduction in tear film quality and ocular surface inflammation. LFA-1 regulates T-cell adhesion, migration, proliferation, and cytokine production and represents a target for therapeutic intervention.

About SAR 1118

SAR 1118 is a potent novel small molecule lymphocyte function-associated antigen-1 (LFA-1; CD11a/CD18; alpha L beta 2) antagonist that can be targeted against a broad range of ocular inflammatory conditions including dry eye, uveitis, and diabetic macular edema. LFA-1 is member of the integrin family of adhesion receptors found on the surface of all leukocytes and represents a therapeutic target of the immune system central to a number of inflammatory stimuli, whether mediated by cytokines, prostaglandins, leukotrienes or complement. SAR 1118 has demonstrated significant potency in in vitro models in inhibiting cell adhesion, cytokine production, and cellular proliferation.

About SARcode Corporation

SARcode is a venture-backed biopharmaceutical company focused on the development of best in class small molecule LFA-1 antagonists as novel nonsteroidal immunomodulators/anti-inflammatory agents for the treatment of T-cell mediated inflammatory diseases. Institutional investors include Alta Partners and Clarus Venture Partners.

For contact information, visit www.sarcode.com


'/>"/>
SOURCE SARcode Corporation
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. SARcode and Sunesis Announce Start of Phase 1 Clinical Trial in Ocular Inflammatory Diseases
2. United Therapeutics Corporation To Announce First Quarter 2010 Financial Results Before Market Open on Thursday, April 29, 2010
3. Usability Sciences Corporation Launches WebIQ Pharma - An Intelligent Survey Tool That Allows Pharma Sites to Measure and Improve Website Effectiveness
4. Kensey Nash Corporation Announces the Addition of Donald Morel, Jr., Ph.D. to Its Board of Directors
5. Providence Service Corporation Releases Fourth Quarter and Year End 2009 Results
6. CVS Caremark Corporation Announces Quarterly Dividend
7. ASPEX Corporation is Shifting the Identity of SEMs
8. PDS Biotechnology Corporation Awarded $1.28M National Cancer Institute Contract
9. CSE Corporation Imposes Recall on SR-100 for Evaluation
10. Dialysis Corporation of America Announces Fiscal Year 2009 Earnings Release Date
11. Somanetics Corporation To Release First Quarter 2010 Financial Results and Host Conference Call March 17, 2010
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... June 24, 2016  Consumers have taken a ... have placed more emphasis on patient outcomes. ... programs in the pharmaceutical industry have evolved beyond ... pharmaceutical companies are focusing on becoming more patient-oriented ... products and services that improve health. ...
(Date:6/24/2016)... -- Research and Markets has announced ... Applications, Technologies, Forecasts" report to their offering. ... Smart Skin, Structural Health Monitoring, Composite Smart Structures, ... involves electronic and/or electrical components and circuits that ... such as vehicle bodies or conformally placed upon ...
(Date:6/24/2016)... PUNE, India , June 24, 2016 ... "Pen Needles Market by Type (Standard Pen Needles, Safety ... 12mm), Therapy (Insulin, GLP-1, Growth Hormone), Mode of Purchase ... published by MarketsandMarkets, This report studies the market for ... is expected to reach USD 2.81 Billion by 2021 ...
Breaking Medicine Technology:
(Date:6/26/2016)... ... June 26, 2016 , ... PawPaws brand pet supplements owned by ... to enhance the health of felines. The formula is all-natural and is made from ... the PawPaws Cat Kidney Support Supplement Soft Chews are Astragalus Root Extract ...
(Date:6/26/2016)... Birmingham, Lake Orion, Clarkston, Michigan (PRWEB) , ... ... ... their direction with respect to fertility once they have been diagnosed with endometriosis. ... for tolerable intercourse but they also require a comprehensive approach that can help ...
(Date:6/25/2016)... ... June 25, 2016 , ... Austin residents seeking Mohs surgery ... of Mohs Surgery and to Dr. Russell Peckham for medical and surgical dermatology. , ... for skin cancer. The selective fellowship in Mohs Micrographic Surgery completed by Dr. Dorsey ...
(Date:6/25/2016)... ... 25, 2016 , ... "With 30 hand-drawn hand gesture animations, FCPX users can ... CEO of Pixel Film Studios. , ProHand Cartoon’s package transforms over 1,300 hand-drawn ... X . Simply select a ProHand generator and drag it above media or text ...
(Date:6/25/2016)... ... June 25, 2016 , ... As a lifelong Southern Californian, ... and his M.D from the David Geffen School of Medicine at UCLA. He trained ... Angeles to complete his fellowship in hematology/oncology at the UCLA-Olive View-Cedars Sinai program where ...
Breaking Medicine News(10 mins):